Kenya National Cancer Control Programme (NCCP) FHIR Implementation Guide, published by Digital Health Agency (DHA), Kenya. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/IntelliSOFT-Consulting/nccpFHIRIG/ and changes regularly. See the Directory of published versions
<MedicationStatement xmlns="http://hl7.org/fhir">
<id value="PriorSystemicTherapyStatementExample"/>
<meta>
<profile
value="https://nshr-uat.sha.go.ke/fhir/StructureDefinition/nccp-prior-systemic-therapy-statement"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>5 years of adjuvant tamoxifen for ER+ breast cancer (2018–2023) prior to current recurrence</p></div>
</text>
<status value="completed"/>
<category>
<coding>
<system
value="https://nshr-uat.sha.go.ke/fhir/CodeSystem/med-clinical-category-cs"/>
<code value="HORMONAL-THERAPY"/>
<display value="Hormonal Therapy"/>
</coding>
</category>
<medicationCodeableConcept>
<coding>
<system
value="https://nshr-uat.sha.go.ke/fhir/CodeSystem/generic-products-cs"/>
<code value="TAMOXIFEN"/>
<display value="Tamoxifen"/>
</coding>
</medicationCodeableConcept>
<subject>🔗
<reference value="Patient/example-patient"/>
</subject>
<effectivePeriod>
<start value="2018-03-01"/>
<end value="2023-02-28"/>
</effectivePeriod>
<reasonReference>🔗
<reference value="Condition/example-condition"/>
</reasonReference>
<note>
<text
value="Completed 5 years of adjuvant tamoxifen. Switched to letrozole following menopause in 2021."/>
</note>
</MedicationStatement>